WINRHO SDF 15000 UNIT — DIN 02302608
ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) : 15000 UNIT · KI BIOPHARMA LLC · SOLUTION · wholesale supply in Canada
Health Canada status: APPROVED
What is WINRHO SDF?
WINRHO SDF 15000 UNIT contains ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) : 15000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02302608, held by KI BIOPHARMA LLC, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 27-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is WINRHO SDF used for?
WinRho SDF, Rh o (D) Immunoglobulin (Human) is indicated for the prevention of Rh immunization in Rho (D) negative mothers not previously sensitized to the Rho (D) factor. WinRho SDF is recommended for prevention of Rh immunization of Rh o (D) negative women at risk of developing Rh antibodies. Rh o (D) Immunoglobulin (Human) prevents the development of Rh antibodies in the Rho (D) negative and previously not sensitized mother carrying a Rho (D) positive fetus, thus preventing the occu rrence of hemol ytic disease in the fetus or the newborn. WinRho SDF is recommended to prevent alloimmunization in Rh o (D) negative female children and female adults in their child - bearing years transfused with Rh o (D) positive RBCs or blood components with Rh o (D) positive RBCs. WinRho SDF is recommended in the treatment of destructive thrombocytopenia of an immune etiology in situations where platelet counts must be increased to control bleeding. WinRho SDF is recommended in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage for the treatment of non - splenectomized Rh o (D) positive 1) children with chronic or acute ITP, 2) adults with chronic ITP, or 3) chi ldren and ad ults with ITP secondary to HIV infection.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Anti-D (Rh) Immunoglobulin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Anti-D (Rh) Immunoglobulin, across 11 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| KI BIOPHARMA LLC | 5 | 2 | WINRHO SDF | Sourceable in Canada |
| APTEVO BIOTHERAPEUTICS LLC | 3 | 0 | WINRHO SDF | No marketed DIN |
| RH PHARMACEUTICALS INC. | 2 | 0 | WINRHO SD KIT INJ, WINRHO SD KIT INJ. | No marketed DIN |
| CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | 1 | 0 | HYP RHO D INJ 16.5% | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 15000 UNIT |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Pack configuration (monograph) | Single-Dose Vials: 600 international units (120 mcg), 1,500 international units (300 mcg), 2,500 international units (500 mcg), 5,000 international units (1,000 mcg), 15,000 international units (3,000 mcg) |
| Storage | STORAGE AND STABILITY |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Anti-D (Rh) Immunoglobulin |
|---|---|
| ATC code | J06BB01 |
| AHFS class | 28:08.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02302608 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2302608 |
| Brand name | WINRHO SDF |
| Generic / active ingredient | ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) : 15000 UNIT |
| Market authorization holder | KI BIOPHARMA LLC |
| Health Canada schedule | Schedule D |
| ATC code | J06BB01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J06BB |
| Current status | APPROVED |
| Status date | 27-Jun-2022 |
| Original market date | 2008-05-12 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| WINRHO SDF | 600 UNIT | SOLUTION | KI BIOPHARMA LLC | MARKETED | 02302551 |
| WINRHO SDF | 1500 UNIT | SOLUTION | KI BIOPHARMA LLC | MARKETED | 02302578 |
| HYP RHO D INJ 16.5% | 16.5 % | LIQUID | CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | CANCELLED POST MARKET | 00083267 |
| WINRHO SD KIT INJ | 120 MCG | KIT | RH PHARMACEUTICALS INC. | CANCELLED POST MARKET | 02022842 |
| WINRHO SD KIT INJ. | .9 % | KIT | RH PHARMACEUTICALS INC. | CANCELLED POST MARKET | 02022834 |
| WINRHO SDF | 5000 UNIT | SOLUTION | KI BIOPHARMA LLC | DORMANT | 02302594 |
| WINRHO SDF | 600 UNIT | KIT | APTEVO BIOTHERAPEUTICS LLC | CANCELLED POST MARKET | 02217430 |
| WINRHO SDF | 1500 UNIT | KIT | APTEVO BIOTHERAPEUTICS LLC | CANCELLED POST MARKET | 02217449 |
| WINRHO SDF | 5000 UNIT | KIT | APTEVO BIOTHERAPEUTICS LLC | CANCELLED POST MARKET | 02230397 |
| WINRHO SDF | 2500 UNIT | SOLUTION | KI BIOPHARMA LLC | APPROVED | 02302586 |
2 · Same class — other molecules in ATC J06BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Hepatitis B Immunoglobulin | H-BIG · HEPAGAM B · HYPERHEP B · HYPERHEP B S/D · +1 more | 9 | 3 | Yes |
| Anti-D (Rh) Immunoglobulin | HYP RHO D INJ 16.5% · WINRHO SD KIT INJ · WINRHO SD KIT INJ. · WINRHO SDF | 11 | 2 | Yes |
| Rabies Immunoglobulin | HYPERAB RABIES IMMUNE GLOBULIN HUMAN · HYPERRAB · HYPERRAB S/D · IMOGAM RABIES INJ 150UNIT/ML · +2 more | 7 | 2 | Yes |
| Tetanus Immunoglobulin | HYPER TET · HYPERTET · HYPERTET S/D | 4 | 1 | Yes |
| Varicella/Zoster Immunoglobulin | VARICELLA ZOSTER IMMUNE GLOBULIN INJ · VARICELLA-ZOSTER IMMUNE GLOBULIN (HUMAN) · VARIZIG | 4 | 1 | Yes |
| Cytomegalovirus Immunoglobulin | CYTOGAM | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J06B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J06BA | Immunoglobulins, Normal Human, For Extravasc. Adm · Immunoglobulins, Normal Human, For Intravasc. Adm. | 50 | 16 |
| J06BD | Casirivimab And Imdevimab · Nirsevimab · Palivizumab · Sipavibart · Sotrovimab · +1 more | 11 | 2 |
| J06B | Immunoglobulins | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.